PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM)

被引：3
|
作者：
Alsina, M.
Lonial, S.
Weber, D. M.
Coutre, S. E.
Kang, B. P.
Glynos, T.
Warsi, G.
Snodgrass, S. M.
Richardson, P. G.
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS308
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE
    Moreau, P.
    San-Miguel, J.
    Hungria, V.
    Yoon, S. S.
    Beksac, M.
    Dimopoulos, M.
    Elghandour, A.
    Jedrzejczak, W.
    Guenther, A.
    Nakorn, T. Na
    Siritanaratkul, N.
    Schlossman, R.
    Hou, J.
    Lonial, S.
    Lee, J. H.
    Einsele, H.
    Sopala, M.
    Bengoudifa, B. -R.
    Corrado, C.
    Richardson, P.
    HAEMATOLOGICA, 2015, 100 : 80 - 81
  • [32] Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study
    Laubach, Jacob P.
    Schjesvold, Fredrik
    Mariz, Mario
    Dimopoulos, Meletios A.
    Lech-Maranda, Ewa
    Spicka, Ivan
    Hungria, Vania T. M.
    Shelekhova, Tatiana
    Abdo, Andre
    Jacobasch, Lutz
    Polprasert, Chantana
    Hajek, Roman
    Illes, Arpad
    Wrobel, Tomasz
    Balari, Anna Sureda
    Beksac, Meral
    Goncalves, Iara
    Creixenti, Joan Blade
    Rajkumar, S. Vincent
    Chari, Ajai
    Lonial, Sagar
    Spencer, Andrew
    Maison-Blanche, Pierre
    Moreau, Philippe
    Richardson, Paul G.
    San-Miguel, Jesus F.
    BLOOD, 2020, 136
  • [33] A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)
    Jamie, Cavanagh
    Baylon, Honorata Giongco
    Caguioa, Priscilla B.
    Davies, Faith E.
    Gharibo, Mecide
    Akinaga, Shiro
    Kurman, Michael R.
    Novak, Barbara A.
    Yong, Kwee L.
    BLOOD, 2013, 122 (21)
  • [34] A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Reu, Frederic J.
    Valent, Jason
    Malek, Ehsan
    Sobecks, Ronald M.
    Faiman, Beth M.
    Hamilton, Kimberly
    Elberson, Jamie
    Fada, Sherry
    Liu, Hien K.
    Samaras, Christy
    Smith, Mitchell R.
    BLOOD, 2015, 126 (23)
  • [35] A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM).
    Richardson, Paul
    Lonial, S.
    Jakubowiak, A.
    Wolf, J.
    Krishnan, A.
    Densmore, J.
    Singhal, S.
    Ghobrial, I.
    Schwartzberg, L.
    Colson, K.
    Harris, J.
    Kendall, T.
    Martineau, I.
    Obadike, N.
    Sullivan, K.
    Pearson, S.
    Hideshima, T.
    Lai, L.
    Sportelli, P.
    Gardner, L.
    Birch, R.
    Henderson, I. C.
    Anderson, K. C.
    BLOOD, 2006, 108 (11) : 1023A - 1023A
  • [36] A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and IV Bortezomib in Patients with Relapsed Multiple Myeloma.
    Siegel, David
    Sezer, Orhan
    Miguel, Jesus F. San
    Mateos, Maria-Victoria
    Prosser, Ian
    Cavo, Michele
    Jalaluddin, Muhammad
    Hazell, Katharine
    Bourquelot, Priscille M.
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 960 - 961
  • [37] Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial
    Majer, Istvan
    Krishna, Arun
    van de Wetering, Gijs
    San-Miguel, Jesus F.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [38] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [39] Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study
    San Miguel, Jesus
    Hungria, Vania T. M.
    Yoon, Sung-Soo
    Beksac, Meral
    Dimopoulos, Meletios A.
    Elghandour, Ashraf
    Jedrzejczak, Wieslaw Wiktor
    Guenther, Andreas
    Nakorn, Thanyaphong Na
    Siritanaratkul, Noppadol
    Schlossman, Robert L.
    Hou, Jian
    Moreau, Philippe
    Lonial, Sagar
    Lee, Jae-Hoon
    Einsele, Hermann
    Salwender, Hans
    Sopala, Monika
    Redhu, Suman
    Paul, Sofia
    Corrado, Claudia
    Binlich, Florence
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [40] Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Richardson, Paul G.
    Guenther, Andreas
    Sezer, Orhan
    Siegel, David
    Blade, Joan
    LeBlanc, Richard
    Sutherland, Heather
    Sopala, Monika
    Mishra, Kaushal K.
    Mu, Song
    Bourquelot, Priscille M.
    Victoria Mateos, Maria
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3696 - +
12345